3H (Suzhou) Pharmaceuticals

3H (Suzhou) Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for oncology and autoimmune diseases. Founded in 2021 by Dr. Shaojing Hu, a co-founder of Betta Pharmaceuticals and Jacobio, the company utilizes its SBCA (Structure Biology, CADD, and AIDD) platform to design high-selectivity small molecules, monoclonal antibodies, and next-generation antibody-drug conjugates (ADCs). Its lead pipeline candidates include 3HP-2827, a selective FGFR2 inhibitor in Phase 1/2 trials for solid tumors, and 3H-10000, an anti-FGFR2b ADC. The company operates research and development facilities in Shanghai and Suzhou, aiming to address unmet medical needs through precision medicine and structural biology-driven drug design.